Graft Versus Host Disease

Graft Versus Host Disease

A Qualitative Exploration of Quality of Life Issues in Individuals With Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant and Their Experiences of a Specialist Multidisciplinary Bone Marrow Transplant Service

This study conducts a primary explorative qualitative study of the experience of QOL issues and multidisciplinary care in patients with chronic GVHD following allogeneic stem cell transplantation. 

Longitudinal Dynamics of Gut Bacteriome, Mycobiome and Virome after Fecal Microbiota Transplantation in Graft-versus-Host Disease

This study reports longitudinal dynamics of the gut bacteriome, mycobiome and virome in a teenager with GvHD after receiving four doses of FMT at weekly interval.

Feasibility of Reduced-Dose Posttransplant Cyclophosphamide and Cotransplantation of Peripheral Blood Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells for SAA

Posttransplant cyclophosphamide as GVHD prophylaxis is an effective strategie for patients receiving MSD-HSCT and haplo-HSCT.

Scientific Reports

Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.

This study describes the economic burden associated with cGVHD.

European Journal of Health Economics
Spatio-Temporal Bone Remodeling after Hematopoietic Stem Cell Transplantation

The interaction of hematopoietic cells and the bone microenvironment to maintain bone homeostasis is increasingly appreciated.

International Journal of Molecular Sciences
Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge

This study presents a case of GVHD in liver transplant and our treatment experience with novel immunotherapeutic agents.

Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease

The main goal of this review is to identify potential novel biomarkers for cGvHD besides the widely accepted molecular and cellular biomarkers.

Frontiers in Immunology
COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters)

A hypothesis is herein advanced that, as with aGVHD, lung stem cell targeting is a potential co-factor in explaining age-related severity of COVID-19 infection.

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

The effect of telomere length on NRM was most prominent after higher intensity conditioning and in patients with severe acute graft-versus-host disease.


Tear proteomic profile in three distinct ocular surface diseases: keratoconus, pterygium, and dry eye related to graft-versus-host disease

This study aimed to evaluate tear proteomic profile in 3 distinct ocular diseases: keratoconus, severe dry eye related to GvHD and pterygium.

Key Metabolic Pathways in MSC-Mediated Immunomodulation: Implications for the Prophylaxis and Treatment of Graft Versus Host Disease

MSCs have been employed as a cellular immunotherapy in diverse preclinical models and clinical trials, but most commonly as agents for the prophylaxis or therapy of GvHD after...

Frontiers in Immunology
Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells

Cell-based therapy for acute graft-versus-host disease may enable induction of donor-specific tolerance in the preclinical setting.

Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes

This study explored the efficacy of low-dose rabbit antithymocyte globulin in MSD-HSCT for patients with acute leukemia or myelodysplastic syndrome.

Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease

The objective of this study was to describe the harm outcomes reported among patients receiving second- and third-line treatment as part of the management for GvHD...

Preclinical Studies of MSC-Derived Extracellular Vesicles to Treat or Prevent Graft Versus Host Disease: a Systematic Review of the Literature.

Treating and preventing GVHD after allogeneic HCT remains a significant challenge.The use of mesenchymal stromal cell-derived extracellular vesicles appears...

Stem Cell Reviews and Reports
Female urethral stricture from chronic graft-versus-host disease

Female urethral strictures are rare with limited literature to guide management. This study presents a case of a 27 year old female diagnosed with a urethral stricture secondary...

Urology case reports
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.

The purpose of this study is to identify the efficacy of ruxolitinib in HLA haplo-HSCT recipients with multidrug-resistant (MDR)-graft-versus-host disease...

Annals of Hematology
The role of the microbiome in the pathogenesis and severity of GvHD

Intestinal microbiota is thought to play a role as a modulator in the pathophysiology of GvHD, via stimulation and differentiation of donor T cells or consequent innate immune-inflammatory mediator

Multiple strictures of the small intestine demanding surgical intervention as a rare consequence of graft versus host disease – case report

Intestinal strictures are an extremely rare and life-threatening complication in patients undergoing allogenic hematopoietic stem cell transplantation.

Annals of Pediatric Surgery
Effect of Remestemcel-L Treatment in Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Biomarker Substudy

The aim of the biomarker substudy was to explore the effect of remestemcel-L treatment on biomarkers involved in disease processes in aGVHD and which have established...

New Biomarker May Help Identify Patients at Risk for Graft-Versus-Host Disease

This report sheds light on immune cell biomarkers that may reveal which patients are most at risk for GVHD, a life-threatening condition that can arise after HSCT for treatment of...

Oncology Times - Latest Articles
Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases

Pre-transplant comorbidities, which may impact the success of allogeneic stem cell transplantation can be appreciated through 3 different scoring systems.

Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India

This study investigates the experience with etanercept as the initial agent in SR aGVHD.

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

This study investigated the clinical efficacy of ruxolitinib and its safety profile in patients having SR-cGVHD after allo-SCT during the treatment course.

Use of Prebiotics as GvHD Prophylaxis

In a single-center, case-controlled study, the authors investigated the impact of prebiotic administration prior to conditioning for allo-HSCT through to Day 28, on the development of mucositis...<

Consensus reached on initial treatment of acute graft-versus-host disease in patients who receive bone marrow transplant; nothing definitive yet for secondary treatment

Dr. Jeanne Palmer discusses treatments for bone marrow transplant patients with acute graft-versus-host disease.

Restoration of gut microbial diversity by donor FMT could resolve GI GvHD

The critical role of gut microbiota in GI GvHD and the potential of donor fecal microbiota transplantation has been previously suggested based on clinical data.

CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation

In this retrospective analysis, it is demonstrated that early CD4+ IR is associated with survival after moderate to severe aGvHD.

Pomalidomide in Chronic GvHD – Efficacy and Safety

In this single-center, randomized phase II trial, the authors investigated the safety and efficacy of pomalidomide in treating moderate to severe cGvHD refractory to prior therapies and...

Preventing transfusion‐associated graft‐versus‐host disease with blood component irradiation: indispensable guidance for a deadly disorder

TA‐GvHD is a rare but largely fatal complication of transfusion characterized by fever, rash, diarrhea, hepatitis and pancytopenia 2–30 days after transfusion.

Lysosomal Acid Lipase Is Required for Donor T Cells to Induce Graft-versus-Host Disease

This study reveals the role of LAL in T cell alloresponse and pathogenicity and validates LAL as a target for controlling GVHD and tumor relapse after allo-HCT.


source list reference